Earnings Preview: Syndax Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Syndax Pharmaceuticals (NASDAQ:SNDX) is scheduled to release its quarterly earnings report on February 27, 2024, with an expected EPS of $-0.99. Investors are hopeful for a beat on this estimate and positive future guidance. Historically, SNDX's stock price has shown mixed reactions to past earnings, with a slight overall decline of 5.92% over the last year. The company's past performance includes beating the EPS estimate last quarter, which led to a minor share price increase of 0.14% the following day.
February 26, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Syndax Pharmaceuticals is anticipated to report an EPS of $-0.99 for the upcoming quarter, with investors keen on positive guidance for future growth. The stock has experienced a slight decline over the past year, indicating a cautious outlook from long-term shareholders.
Given SNDX's history of mixed reactions to earnings reports and the overall negative performance over the last year, the short-term impact of the upcoming earnings report is uncertain. While a beat on the EPS estimate and positive guidance could provide a boost, the stock's recent trend suggests a cautious approach. The importance is rated high due to the potential for future guidance to influence investor sentiment.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100